Combinaton of radiation and hormone suppression therapy shown to effectively treat early-stage prostate cancer

September 11, 2000

Results similar to success in treating advanced-stage cancers

BOSTON -- In the first study of its kind, researchers at Brigham and Women's Hospital (BWH) and Dana-Farber Cancer Institute (DFCI) have found that combined radiation therapy (RT) and androgen suppression therapy (AST) is a more effective treatment for localized, early-stage prostate cancer compared to treatment using radiation therapy alone. The findings are published in the September 13th issue of JAMA (Journal of the American Medical Association).

"Previous studies have shown a benefit to treating advanced-stage prostate cancer with radiation and hormone therapy," said Anthony V. D'Amico, MD, PhD, of BWH and DFCI. "This is the first study to show that the combination treatment may also benefit people with early-stage cancer."

Prostate cancer is the second leading cause of cancer death among men in this country. The American Cancer Society estimates that about 184,500 American men will be diagnosed with the disease this year and 39,200 will die.

In the study, researchers compared the relative risk of prostate specific antigen (PSA) failure during a five-year period in men who underwent RT and AST as treatment for diagnosed early-stage prostate cancer compared with men who received RT.

Although no significant difference between treatment groups was found in patients in the low-risk category, men who were classified in the intermediate-risk group and received both therapies for their cancer were five times less likely to have PSA failure than men who received RT alone. For men in the high-risk group who received both RT and AST, the effectiveness of combination therapy was more profound; they were two and one-half times less likely to have PSA failure than men who had received RT. "While further research is needed, it appears that the one-two punch of RT and AST may be a more effective treatment in the battle against both advanced-stage and early-stage prostate cancer," added Dr. D'Amico.

The 1,586 study participants were categorized using a combination of their PSA levels, biopsy Gleason score, and stage of tumor into three groups. All patients in the study had cancer that was localized to the prostate by rectal exam. The more aggressive the participant's tumor, the higher the risk category in which he was placed. The men's cancers were treated using a three-dimensional conformal RT with or without AST.

AST is a type of hormonal therapy that is often used in all phases of prostate cancer treatment to help block production or action of the male hormones that have been shown to fuel prostate cancer.

Dana-Farber Cancer Institute

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to